Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals (Nasdaq: OLMA) announced the granting of stock options to two new employees totaling 40,400 shares, effective November 1, 2022. This decision was approved by the Compensation Committee under the 2022 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, with an exercise price of $3.72 per share. Olema focuses on developing targeted therapies for women’s cancers, notably its lead candidate OP-1250, which has received FDA Fast Track designation and is currently in Phase 2 trials.
- Olema granted stock options to two new employees for 40,400 shares.
- The stock options have a 10-year term and an exercise price of $3.72 per share.
- Olema's lead product candidate, OP-1250, has received FDA Fast Track designation.
- None.
SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to two new employees to purchase an aggregate of 40,400 shares of the Company's common stock, effective as of November 1, 2022. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan, with a grant date of November 1, 2022, as an inducement material to the new employee entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK 4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.
Contact:
Shane Kovacs, COO and CFO
ir@olema.com
FAQ
What stock options did Olema Pharmaceuticals grant on November 1, 2022?
What is the exercise price of the stock options awarded by Olema?
What are the vesting terms for Olema's stock options?
What is Olema's lead product candidate and its clinical status?
Has OP-1250 received any special designations from the FDA?
